Skip to main content
Equibles
PTPI logo

PTPI · Petros Pharmaceuticals, Inc.

Track PTPI — free

Use PTPI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PTPI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.05 -0.02 (-28.79%) At close · May 22
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Because the Company does not have sufficient resources to fund its operations for the next twelve months from the date of this filing, management has substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$169,489
Shares
42.37M
Volume · May 22 10.28M Avg daily vol (16 sessions) 38.33M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.05 Open$0.02 Day$0.02–0.06 52W close$0.05–16.25 Avg vol 30d22.4M Short int754 · 0.0% float · 1.0d Short vol52% DataDec 2020–May 2025 Filing10-Q · Aug 13

Up next

Latest filing: 10-Q
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$5.11M
Trailing 12 months
Net income (TTM)
−$3.20M
Trailing 12 months
Revenue growth YoY
-12.2%
Year over year
Operating margin
-90.5%
Trailing 12 months
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 18,468.1%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+82.8%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
—
Latest settlement
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −99%
below
Price vs 50-day avg −96%
below
RSI (14) 27
oversold
MACD trend Positive
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −96%
trailing
6-month return −99%
trailing
YTD return −100%
this year
Relative strength −96%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $1 › 200d $6 — 200d above 50d
Institutional flow Accumulating
+60% holders QoQ · +6 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
16 holders — mid 3-yr range
Fundamentals
Fair
Revenue growth −12%
Y/Y
Gross margin 76%
expanding
EPS growth +98%
Y/Y
Free cash flow $-6.8M
Quant / Vol
risk profile
Very High
Volatility 230%
annualized · 1-yr
Max drawdown −100%
past year
ATR 374.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−99% Bearish
Price vs 50-day avg
−96% Bearish
RSI (14)
27 Neutral
MACD trend
Positive Bullish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross) No cross
50d $1 › 200d $6 — 200d above 50d
Institutional flow Accumulating
+60% holders QoQ · +6 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
16 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $16
vs 200-day avg -99% vs 50-day avg -96%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PTPI
Petros Pharmaceuticals, Inc.
this stock
$169,489 — -12.2% — 0.0%
TAK
Takeda Pharmaceutical Co Ltd
 $62.65B +28.8% — — 0.1%
GALDY
Galderma Group AG/ADR
 $48.88B +1.1% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $48.14B +30.9% +4.3% 67.7 2.6%
HLN
Haleon plc
 $44.72B +0.6% — — 0.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
16
% held
0.1%
Net QoQ
+41.3K sh
Top holder
JANE STREET GROUP, LLC
Held Float
View
Short & Settlement
Short Interest
Shares short
754
Days to cover
1.0d
Change
0 sh
View
Short Volume
Short vol %
52%
As of
Aug 21, 2026
Short Total
View
Fails to Deliver
FTD shares
2
Value
$0
As of
Apr 15, 2026
View
Off-Exchange
Off-exchange %
35.8%
Week of
May 19, 2025
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$5.1M
Net income (FY)
$1.9M
EPS diluted
$-1.56
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 30, 2026
This year
8
View
Exempt Offerings
Offering
$30.0M
Filed
Jul 21, 2023
View

Performance

5D 20D 120D MTD YTD
PTPI -70.6% -96.3% -99.3% -84.3% -99.5%
SPY -1.3% +6.7% -2.9% +5.2% -0.5%
vs SPY -69.4% -103.0% -96.4% -89.5% -99.0%
Key facts CIK 1815903 CUSIP 71678J308 Visit website Investor relations